AIRS vs BIO · rev $180.3M vs rev $2.58B
Airsculpt Technologies Inc (AIRS) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
Airsculpt Technologies Inc (AIRS) is a medical care facilities company listed on US.
BIO (BIO) common stock.
Latest reported AIRS revenue for 2024-12-31 was $180.3M. Net income was -$8.3M. Revenue was down 7.9% from 2023-12-31 to 2024-12-31. AIRS currently screens at market cap $337.0M.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
AIRS currently screens at market cap $337.0M. BIO currently screens at market cap $0.
Not investment advice. Open the AIRS and BIO stock pages for the full models.
Not investment advice.